Enabling Safe Cell & Gene Therapies
Scaling Genomic Safety Validation for CGT Programs.
Our Mission
At Countagen, we are a team of molecular biologists and biotechnologists dedicated to solving the most persistent bottlenecks in genome editing analysis.
LockSeq was engineered to minimize dropouts, remove stochastic noise and amplification biases—providing researchers with a high-fidelity molecular lock for their most critical R&D milestones.
The Team & Founding Heritage
Countagen was founded upon decades of breakthrough research into padlock probe chemistry and molecular diagnostics conducted at Karolinska Institutet and SciLifeLab.
The company is led by Felix Neumann, PhD (CEO) and Iván Hernández-Neuta, PhD (CSO). Together, they have industrialized padlock probes into the LockSeq platform, focusing on high-fidelity genome editing analysis for Cell and Gene Therapy developers.
Founding Pioneers: Countagen's scientific foundation was established by a world-class founding team of pioneers in molecular tools:
-
Prof. Mats Nilsson: A primary inventor of padlock probe and rolling circle amplification (RCA) technologies and Professor at Stockholm University/SciLifeLab.
-
Malte Kühnemund, PhD: An expert in molecular diagnostic tool development and biotech entrepreneurship.
-
Mårten Winge: A veteran biotech executive with a proven track record in scaling high-impact life science platforms.
This combination of deep academic heritage and industrial focus ensures that Countagen remains at the cutting edge of precision genomics.
Location & Contact
Countagen AB
Solna, Stockholm County
Sweden
Located within the Karolinska Institutet / SciLifeLab biotech ecosystem.